Seviteronel - Emerging Drug Insight and Market Forecast - 2030
|出版商||DelveInsight Business Research LLP||商品編碼||959716|
|出版日期||按訂單生產||內容資訊||英文 50 Pages
|Seviteronel:新藥的洞察與市場預測 (2030年) Seviteronel - Emerging Drug Insight and Market Forecast - 2030|
|出版日期: 按訂單生產||內容資訊: 英文 50 Pages||
Seviteronel(INO-464)是一種選擇性的CYP17裂解酶和AR抑製劑，由Viamet Pharmaceuticals的科學家發明的相關化合物的多個專利化學類別的廣泛集合由Innocrin完全擁有。 Innocrin已確定具有高CYP17裂解酶效力和選擇性的高優先級潛在顧客。 Innocrina的目的是利用其組織專業知識將這些第二代潛在顧客中的一個或多個推進臨床開發。除可用於治療乳腺癌和CRPC以外，靶向CYP17裂解酶和AR的抑製劑還具有治療其他由AR驅動的癌症的潛能，包括卵巢癌，膀胱癌，肝細胞癌和肺癌。
本報告提供前列腺癌症、乳癌等的治療藥物Seviteronel的市場結構、趨勢相關分析，產品概要 (用法、容量，作用機制等) 和相關法規，產品開發、臨床實驗的進展， 主要7個國家(美國，歐洲5個國家 (德國，法國，義大利，西班牙，英國)，日本)的市場規模趨勢預測 (2020∼2030年)，市場競爭狀態、SWOT分析，其他的治療藥的競爭狀態，資本交易的動向，今後的市場成長可能性等調查、考察。
"Seviteronel- Emerging Drug Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Prostate cancer in 7 Major Markets. A detailed picture of the Seviteronel in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
Seviteronel (INO-464) is a selective CYP17 lyase and AR inhibitor and the broad collection of multiple patented chemical classes of related compounds that were invented by scientists at Viamet Pharmaceuticals are wholly owned by Innocrin. Innocrin has identified high priority leads that have high CYP17 lyase potency and selectivity. It is Innocrina€s intent to leverage its organizational expertise to advance one or more of these 2nd-generation leads into clinical development. In addition to their potential use for the treatment of breast cancer and CRPC, inhibitors that target both CYP17 lyase and AR also have potential for the treatment of other cancers driven by the AR including ovarian, bladder, hepatocellular, and lung. Similarly, these inhibitors may also have commercial potential for the treatment of non-oncologic syndromes that are due to excess sex steroid production. These conditions include endometriosis, polycystic ovary syndrome, congenital adrenal hyperplasia, and precocious puberty, among others. Safety and convenience are important attributes of our product candidates.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
This report provides a detailed market assessment of Seviteronel in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.
The report provides the clinical trials information of Seviteronel covering trial interventions, trial conditions, trial status, start and completion dates.